Across nearly 5,900 patients, DaVita found steady weight loss and lower hospitalization risk on GLP-1s without hurting fluid removal or kidney function.
Recap by typeshit. Full story at DaVita Newsroom.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Loading…